53 related articles for article (PubMed ID: 18085674)
21. [Chronic myeloid leukemia].
Hochhaus A
Dtsch Med Wochenschr; 2011 Oct; 136(40):2007-10. PubMed ID: 21960328
[No Abstract] [Full Text] [Related]
22. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
23. [Cytogenetic and molecular monitoring of chronic myeloid leukemia].
Kajtár B; Méhes G; Jaksó P; Kereskai L; Iványi JL; Losonczy H; Egyed M; Tóth P; Tóth A; Gasztonyi Z; Dömötör M; Pajor L
Orv Hetil; 2006 May; 147(21):963-70. PubMed ID: 16812971
[TBL] [Abstract][Full Text] [Related]
24. Chronic myeloid leukemia--advances in biology and new approaches to treatment.
Goldman JM; Melo JV
N Engl J Med; 2003 Oct; 349(15):1451-64. PubMed ID: 14534339
[No Abstract] [Full Text] [Related]
25. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
26. [Chronic myeloid leukemia--treatment].
Stoetzer OJ; Hentrich M; Salat C
Dtsch Med Wochenschr; 2002 Dec; 127(49):2621-4. PubMed ID: 12469275
[No Abstract] [Full Text] [Related]
27. [Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia].
Lange T; Pelz-Ackermann O; Burkhardt R; Niederwieser D
Dtsch Med Wochenschr; 2006 Oct; 131(43):2390-4. PubMed ID: 17054054
[No Abstract] [Full Text] [Related]
28. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
29. [Gleevec: an novel inhibitor of bcr-abl tyrosine kinase].
Guo XN; Ding J
Sheng Li Ke Xue Jin Zhan; 2003 Apr; 34(2):183-6. PubMed ID: 12889162
[No Abstract] [Full Text] [Related]
30. Imatinib: the promise of a "magic bullet" for cancer fulfilled.
Henderson CA
J Med Assoc Ga; 2003; 92(1):12-4, 22. PubMed ID: 12743899
[No Abstract] [Full Text] [Related]
31. Harmonization of molecular monitoring of CML therapy in Europe.
Müller MC; Cross NC; Erben P; Schenk T; Hanfstein B; Ernst T; Hehlmann R; Branford S; Saglio G; Hochhaus A
Leukemia; 2009 Nov; 23(11):1957-63. PubMed ID: 19710700
[TBL] [Abstract][Full Text] [Related]
32. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301
[No Abstract] [Full Text] [Related]
33. Clinical pharmacokinetics of imatinib mesylate.
Levêque D; Maloisel F
In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
[TBL] [Abstract][Full Text] [Related]
34. [Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].
Jomen W; Kuroda H; Matsuno T; Sato M; Yamada M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Kato J; Nojiri S
Rinsho Ketsueki; 2014 Mar; 55(3):360-5. PubMed ID: 24681942
[TBL] [Abstract][Full Text] [Related]
35. [Pathophysiology and treatment of acute myeloid leukemia].
Naoe J
Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
[No Abstract] [Full Text] [Related]
36. [Early blastic transformation within a year of imatinib treatment in 2 cases of chronic myeloid leukemia].
Miyazaki K; Kon S; Watanabe T; Togano T; Ohsaka M; Suzuki Y; Danbara M; Horie R; Kanda Y; Maruta A; Higashihara M
Rinsho Ketsueki; 2007 Apr; 48(4):297-304. PubMed ID: 17515120
[TBL] [Abstract][Full Text] [Related]
37. Molecular targets and the treatment of myeloid leukemia.
Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?
Legros L; Cassuto JP; Ortonne JP
Br J Dermatol; 2005 Sep; 153(3):691-2. PubMed ID: 16120179
[No Abstract] [Full Text] [Related]
39. [Trends in molecular targeting therapeutics for chronic myeloid leukemia].
Nagai T
Rinsho Ketsueki; 2007 Oct; 48(10):1360-9. PubMed ID: 17933121
[No Abstract] [Full Text] [Related]
40. Chronic myeloid leukemia in 2006: a perspective.
Mauro MJ; Deininger MW
Haematologica; 2006 Feb; 91(2):152. PubMed ID: 16461297
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
